NASDAQ: XBIOXenetic Biosciences Inc Stock
$3.85+0.09 (+2.39%)
Updated Apr 23, 2024
XBIO Price
$3.85
Fair Value Price
N/A
Market Cap
$5.93M
52 Week Low
$2.55
52 Week High
$5.97
P/E
-1.42x
P/B
0.61x
P/S
2.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.54M
Earnings
-$4.13M
Gross Margin
100%
Operating Margin
-162.78%
Profit Margin
-162.8%
Debt to Equity
0.08
Operating Cash Flow
-$4M
Beta
0.8
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
XBIO Overview
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XBIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XBIO is good value based on its book value relative to its share price (0.61x), compared to the US Biotechnology industry average (5.93x)
P/B vs Industry Valuation
XBIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XBIO due diligence checks available for Premium users.
Be the first to know about important XBIO news, forecast changes, insider trades & much more!
XBIO News
Valuation
XBIO fair value
Fair Value of XBIO stock based on Discounted Cash Flow (DCF)
Price
$3.85
Fair Value
-$3.08
Undervalued by
225.08%
XBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.42x
Industry
16.46x
Market
41.92x
XBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.61x
Industry
5.93x
XBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XBIO's financial health
Profit margin
Revenue
$672.0k
Net Income
-$1.2M
Profit Margin
-174.3%
XBIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
XBIO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.6M
Liabilities
$809.6k
Debt to equity
0.08
XBIO's short-term assets ($9.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XBIO's short-term assets ($9.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XBIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$793.0k
Investing
$0.0
Financing
$0.0
XBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XBIO vs Biotech Stocks
Xenetic Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.